Can amlodipine, Flexeril (cyclobenzaprine), or Cardura (doxazosin) cause bradycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Can These Medications Cause Bradycardia?

Yes, all three medications can cause bradycardia, though through different mechanisms and with varying likelihood: Cardura (doxazosin) has documented bradycardia as a postmarketing adverse effect, amlodipine can cause bradycardia particularly in overdose or acute intoxication (and rarely at therapeutic doses in elderly patients), while Flexeril (cyclobenzaprine) is not associated with bradycardia based on available evidence.

Cardura (Doxazosin)

Doxazosin is documented to cause bradycardia and cardiac arrhythmias in postmarketing surveillance data. 1

  • The FDA label specifically lists bradycardia and cardiac arrhythmias under postmarketing adverse events for doxazosin 1
  • Research demonstrates that doxazosin at 10 μM can prolong PR interval and induce arrhythmias, including complete inhibition of sinus rhythm in experimental models 2
  • A withdrawal study in normotensive subjects showed that discontinuation of doxazosin resulted in bradycardia without hypotension, with decreased pulse rate on both day 2 and day 7 after withdrawal 3

Clinical Mechanism

  • Doxazosin inhibits multiple cardiac ion channels including I(Na), I(Ca,L), I(to), and Iss, which can affect cardiac automatism and conduction 2
  • The bradycardia appears related to effects on the AV nodal tissue through heterogeneous calcium channel blockade 2

Amlodipine

Amlodipine typically does not cause bradycardia at therapeutic doses, but can cause significant bradyarrhythmias in acute intoxication or overdose situations. 4, 5

At Therapeutic Doses

  • The FDA label states that chronic oral administration of amlodipine "did not lead to clinically significant changes in heart rate" in normotensive patients with angina 4
  • Amlodipine "does not change sinoatrial nodal function or atrioventricular conduction in intact animals or man" at therapeutic doses 4
  • When combined with beta-blockers, no adverse effects on electrocardiographic parameters were observed in clinical studies 4

In Acute Intoxication

  • Severe amlodipine intoxication can cause important bradyarrhythmias including low atrial rhythm, prolonged PR interval, atrioventricular block, and bundle branch blocks 5
  • During acute intoxication, dihydropyridines like amlodipine lose their selective vascular action and can depress cardiac automatism and conduction 5
  • A case report documented BRASH syndrome (Bradycardia, Renal failure, AV nodal blockade, Shock, Hyperkalemia) associated with amlodipine in an 89-year-old patient 6

Important Caveat

  • While reflex tachycardia is the expected response to amlodipine's vasodilatory effects, elderly patients or those with renal impairment may paradoxically develop bradycardia 6, 7
  • Drug interactions with SSRIs (fluoxetine, sertraline, paroxetine) can intensify amlodipine's side effects 8

Flexeril (Cyclobenzaprine)

There is no evidence in the provided literature that cyclobenzaprine causes bradycardia. Cyclobenzaprine is a muscle relaxant structurally related to tricyclic antidepressants, but bradycardia is not a recognized adverse effect of this medication based on the available evidence.

Clinical Recommendations

Monitoring Priorities

  • For patients on doxazosin: Monitor heart rate regularly, particularly in elderly patients or those with baseline conduction abnormalities 1, 2
  • For patients on amlodipine: Bradycardia risk is minimal at therapeutic doses, but monitor closely in elderly patients, those with renal impairment, or if overdose is suspected 4, 5, 6
  • Be aware that combination therapy with beta-blockers and sodium channel blockers dramatically increases bradycardia risk, even months after medication initiation 9

High-Risk Scenarios

  • Elderly patients (age >70) are at increased risk for medication-induced bradycardia 6, 9
  • Patients with renal impairment may develop synergistic bradycardia with amlodipine through BRASH syndrome 6
  • Concomitant use of CYP3A4 inhibitors with either amlodipine or doxazosin can increase drug levels and adverse effects 4, 1

Related Questions

Can any of these medications cause bradycardia?
Is amlodipine (a dihydropyridine calcium‑channel blocker) safe to use in patients with bradycardia?
Can amlodipine (calcium channel blocker) cause bradycardia (abnormally slow heart rate)?
What is the best approach to manage a patient with tachycardia, hypertension, type 2 diabetes, hyperlipidemia, major depressive disorder, anxiety, panic disorder, treatment-resistant depression, chronic pain, and treatment-resistant insomnia, who is currently taking metoprolol (Lopressor), telmisartan (Micardis), amlodipine (Norvasc), jardiance (Empagliflozin), mounjaro (Tirzepatide), belsomra (Suvorexant), seroquel (Quetiapine), omeprazole (Prilosec), atorvastatin (Lipitor), buspar (Buspirone), wellbutrin (Bupropion), klonopin (Clonazepam), and naproxen (Naprosyn)?
What is the treatment for symptomatic bradycardia?
What is an appropriate medication simplification plan for a 41-year-old male with schizoaffective disorder, bipolar type, currently on risperidone 4 mg twice daily, Lybalvi (olanzapine/fluoxetine) 10 mg nightly, divalproex (Depakote) 250 mg morning and 500 mg evening, gabapentin 309 mg three times daily, and trazodone 100 mg nightly?
Which medications can reverse opioid‑induced functional urinary retention?
How should a high anion‑gap metabolic acidosis with an alkalotic pH be evaluated and managed?
How many minutes after intravenous (IV) fentanyl administration does it begin to take effect?
Does progesterone therapy increase the risk of hyperpigmentation after ablative laser (CO₂ or Er:YAG) treatment?
What is the appropriate management of hypoalbuminemia associated with Mycobacterium avium complex infection?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.